Halofuginone is a low molecular weight quinazolinone alkaloid that acts as an inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 gene expression. It is being developed as a pharmaceutical active ingredient for research into fibrotic conditions and cancer metastasis.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 868851-54-1
Halofuginone hydrobromide
pharmaceutical raw material
Halofuginone lactate
pharmaceutical raw material
Umeclidinium bromide
pharmaceutical raw material
Neurokinin B
pharmaceutical raw material
Olodaterol hydrochloride
pharmaceutical raw material
Tecovirimat
pharmaceutical raw material
(-)-Halofuginone
pharmaceutical raw material
7-bromo-6-chloro-3-[3-[(2R,3S)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one
LVASCWIMLIKXLA-CABCVRRESA-N
C1C[C@@H]([C@H](NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)Cl)Br)O